Comparative Effect Between Mulligan Leg Raise and Spinal Mobilization With Limb Movement in Lumbar Radiculopathy

November 16, 2026 updated by: Foundation University Islamabad

This study examines the comparative effects of mulligan leg raise traction and Spinal Mobilization with Leg Movement (SMWLM) on lumbar radiculopathy

Study Overview

Detailed Description

Participants were randomly assigned into two groups:

Group A, which recieved leg raise traction Group B, which received SMWLM interventions focusing on spinal mobilization combined with controlled leg movements.

Pain, functional disability, and lumbar range of motion were measured using VAS, ODI, and bubble inclinometer

Study Type

Interventional

Enrollment (Estimated)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Ruqia Begum, MS-OMPT
  • Phone Number: +92 311 5532544
  • Email: ruqia@fui.edu.pk

Study Locations

    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Recruiting
        • Foundation University College of Physical Therapy
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 30 to 50 years
  • Both male and female participants
  • Unilateral lumbar radiculopathy
  • Mild posterolateral disc herniation confirmed on MRI
  • Positive Straight Leg Raise (SLR) test between 30° and 70°
  • Positive crossed Straight Leg Raise test
  • Positive Slump test
  • Pain and symptoms following the L4 and L5 dermatomal pattern

Exclusion Criteria:

  • MRI findings of spinal instability
  • MRI findings of significant neuroforaminal stenosis
  • MRI findings of structural abnormalities requiring surgical intervention (e.g., large disc herniation)
  • Severe neurological deficit or severe motor weakness (Manual Muscle Testing grade 0, 1, or 2)
  • Signs of cauda equina syndrome (e.g., saddle anesthesia, bowel or bladder dysfunction)
  • Diagnosed lumbar spondylolisthesis
  • Lumbar spine fracture
  • Spinal stenosis
  • Spinal tumor
  • Ankylosing spondylitis
  • History of previous spinal surgery
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A mulligan leg raise traction

Group A will receive standard treatment of ELDOA Strengthening will be divided into following phases

  1. Warm up phase:
  2. Strengthening phase:
  3. Cool down phase

Participants will receive a four-week physiotherapy program with three sessions per week. Each session will heat application followed by supervised stretching and strengthening exercises.

and Participants will receive straight leg raise traction.

Experimental: Spinal moblization with limb movement

Group B will receive Standard treatment of spinal mobilzation and limb movement Strengthening will be divided into following phases

  1. Warm up phase:
  2. Strengthening phase:
  3. Cool down phase:

Participants will receive a four-week physiotherapy program with three sessions per week. Each session will heat application followed by supervised stretching and strengthening exercises. and Participants will receive spinal mobilization combined with limb movement along with standard physiotherapy. The technique will be repeated three times.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Lumbar Pain Intensity
Time Frame: Baseline, 2nd week, and 4th week

Pain severity will be measured using the Visual Analog Scale ranging from 0 (no pain) to 10 (worst imaginable pain).

Baseline, 2nd week, and 4th week
Functional Disability
Time Frame: Baseline, 2nd week, and 4th week

Measured by Oswestry Disability Index, a 10-item questionnaire with six response options per item.

Baseline, 2nd week, and 4th week
Lumbar Range of Motion
Time Frame: Baseline, 2nd week, and 4th week

Lumbar spine range of motion (ROM) will be assessed using a universal inclinometer and recorded in degrees (°). Values will be reported for each movement direction (flexion, extension, and right and left lateral flexion) on a range from 0° (no movement) to the normative maximum for the lumbar spine (approximately 60° for flexion, 25° for extension, and 25° for each lateral flexion, per the AMA Guides to the Evaluation of Permanent Impairment). Higher values indicate greater lumbar mobility and therefore a better outcome, whereas lower values indicate greater movement restriction.

Baseline, 2nd week, and 4th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 23, 2026

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 15, 2027

Study Registration Dates

First Submitted

October 14, 2026

First Submitted That Met QC Criteria

October 14, 2026

First Posted (Actual)

October 21, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FUI/FUCP/CTR/MSMSK/MahamFarooq

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe